Powered by


                    Home  |  Forums  |  Humor  |  Advertising  |  Contact
   Health Questions

   News via RSS






   Forum Archives





















   Primary Care






   Other Sections


   Research Tools

   Medical Tutorials

   Medical Software




Back to index

Cancer Chemotherapy Regimen for Ovarian Cancer

 IP-CC                                                ovarian(117)
  cisplatin....... 200 mg/sqm IP over 30 minutes.
  cytarabine...... 2,000 mg IP over 30 minutes.
  FREQUENCY....... Repeat cycle every 28 days.

    Markman M.  Cleary S.  Lucas WE.  Howell SB. Intraperitoneal 
    chemotherapy with high-dose cisplatin and cytosine arabinoside 
    for refractory ovarian carcinoma and other malignancies 
    principally involving the peritoneal cavity. Journal of 
    Clinical Oncology.  3(7):925-31, 1985 Jul. 
    Sixty-two patients with refractory ovarian carcinoma or other 
    malignancies principally confined to the peritoneal cavity 
    were treated with an intraperitoneal combination chemotherapy 
    regimen consisting of cisplatin (100 mg/m2 or 200 mg/m2) and 
    cytosine arabinoside (4 X 10(-3) mol/L or 10(-2) mol/L). 
    Sodium thiosulfate was simultaneously administered 
    intravenously (IV) to protect against cisplatin-induced 
    nephrotoxicity. Sixteen of 52 evaluable patients demonstrated 
    evidence of a clinical response including 14 (36%) of 39 with 
    refractory ovarian carcinoma. Systemic toxicity was not severe 
    except for cisplatin-induced emesis and a single episode of 
    major renal insufficiency. Dose-limiting toxicity was bone 
    marrow suppression with cytosine arabinoside administered at 
    10(-2) mol/L. We conclude that combination intraperitoneal 
    therapy with high-dose cisplatin and cytosine arbinoside can 
    be safely administered with objective tumor responses observed 
    in patients with ovarian carcinoma refractory to front-line 
    chemotherapy and in occassional individuals with other 
    malignancies principally confined to the peritoneal cavity. 

advertisement.gif (61x7 -- 0 bytes)

Are you a doctor or a nurse?

Do you want to join the Doctors Lounge online medical community?

Participate in editorial activities (publish, peer review, edit) and give a helping hand to the largest online community of patients.

Click on the link below to see the requirements:

Doctors Lounge Membership Application


 advertisement.gif (61x7 -- 0 bytes)




We subscribe to the HONcode principles of the HON Foundation. Click to verify.
We subscribe to the HONcode principles. Verify here

Privacy Statement | Terms & Conditions | Editorial Board | About us
Copyright 2001-2012 DoctorsLounge. All rights reserved.